How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Colorado

Why NMN and NR Require a Prescription Path in Colorado

NMN and NR are NAD+ precursors that raise intracellular nicotinamide adenine dinucleotide levels. Neither compound holds FDA approval as a finished drug product. In November 2022, the FDA concluded that NMN had been authorized for investigation as a new drug, which removed it from the dietary supplement category under the Federal Food, Drug, and Cosmetic Act [1]. That ruling did not affect NR (nicotinamide riboside), which remains available as a supplement under the brand name Tru Niagen.

For NMN specifically, the regulatory shift means Colorado consumers cannot legally purchase it over the counter as a supplement. The practical workaround: a licensed prescriber writes a patient-specific prescription, and a 503A compounding pharmacy prepares the formulation. Colorado's State Board of Pharmacy recognizes out-of-state 503A pharmacies that hold a nonresident pharmacy license, so patients are not limited to in-state compounders [2].

NR sits in a different regulatory lane. Because NR retains its supplement status, Coloradans can buy it directly. But many longevity-focused clinicians still prefer to prescribe pharmaceutical-grade NR from a compounder to control purity, dosing precision, and third-party testing. The choice between supplement-grade NR and compounded NR often comes down to the provider's quality threshold.

Telehealth Prescribing: How Colorado Residents Start

Colorado permits synchronous telehealth visits for prescribing NAD+ precursors. A valid prescriber-patient relationship can be established over video under the Colorado Medical Practice Act (C.R.S. § 12-240-107), and no in-person visit is required before the first prescription [3]. That makes the process straightforward for patients in rural areas like the Western Slope or the San Luis Valley.

Here is the standard workflow. You complete an intake form, upload recent labs (or order new ones), and schedule a video consultation. The prescriber reviews your metabolic profile, discusses goals, and writes a prescription to a compounding pharmacy. Most telehealth platforms partner with a specific 503A pharmacy, though you can request a transfer to a compounder of your choice.

Yoshino et al. published one of the first rigorous human trials of NMN in 2021, enrolling 25 postmenopausal women with prediabetes. At 250 mg/day for 10 weeks, NMN improved skeletal muscle insulin sensitivity by roughly 25% compared to placebo, measured by hyperinsulinemic-euglycemic clamp [4]. That trial, though small, gave prescribers clinical data to anchor dosing conversations. Most Colorado telehealth providers now start patients at 250 to 500 mg daily of NMN, adjusting based on follow-up labs at 8 to 12 weeks.

Who Can Write the Prescription in Colorado

Colorado law allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe compounded medications, including NMN. NPs in Colorado have full practice authority under C.R.S. § 12-255-112, meaning they do not need a collaborative agreement with a physician to prescribe [5]. PAs require a supervising physician relationship but can independently write prescriptions within their scope of practice.

The practical difference is minimal. Whether you see an MD at a Denver longevity clinic or an NP through a telehealth platform based in Boulder, the prescription carries the same legal weight at the pharmacy. What matters more is the prescriber's familiarity with NAD+ metabolism, appropriate dosing, and monitoring protocols.

Board-certified physicians in endocrinology, anti-aging medicine (ABAARM), or functional medicine tend to have the deepest experience with these compounds. The American Academy of Anti-Aging Medicine (A4M) maintains a provider directory that includes Colorado-licensed clinicians specializing in NAD+ therapeutics.

Required Labs Before Starting NMN/NR

No universal lab panel exists for NMN/NR prescribing, but most Colorado providers follow a similar baseline protocol. The goal: rule out contraindications, establish metabolic benchmarks, and create a measurable follow-up framework.

A typical pre-prescription panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting insulin, hemoglobin A1c, lipid panel, and liver function tests (ALT, AST). Some providers add a whole-blood NAD+ level or urinary methylation markers (methylmalonic acid, homocysteine) to gauge baseline NAD+ status and methylation capacity [6]. NMN supplementation consumes methyl groups during metabolism, which is why homocysteine monitoring matters for patients with MTHFR polymorphisms.

Martens et al. studied nicotinamide riboside at 1 to 000 mg/day for 6 weeks in healthy middle-aged and older adults (N=24) and found a 60% increase in blood NAD+ levels with no serious adverse effects [7]. Liver enzymes remained stable throughout the trial. That safety data is one reason most providers feel comfortable prescribing NMN/NR after a standard metabolic workup rather than requiring specialized testing.

Follow-up labs are typically drawn at 8 to 12 weeks. Providers look for changes in NAD+ levels, fasting glucose, insulin sensitivity markers, and liver function to confirm the compound is both effective and well tolerated.

503A Compounding Pharmacies Serving Colorado

A 503A pharmacy compounds medications pursuant to individual prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies differ from 503B outsourcing facilities, which can produce batches without patient-specific prescriptions. For NMN, 503A is the relevant pathway because each script is tied to a named patient [8].

Colorado's Board of Pharmacy requires out-of-state compounding pharmacies to hold a nonresident pharmacy license before shipping into the state. Several nationally recognized compounders already carry this license. When selecting a pharmacy, verify three things: current Colorado nonresident license, USP 795/800 compliance for non-sterile compounding, and third-party certificate of analysis (COA) for NMN purity.

Turnaround times vary. In-state 503A pharmacies in the Denver metro area (Arvada, Littleton, Colorado Springs) can often fill a compounded NMN prescription in 3 to 5 business days. Out-of-state pharmacies that ship to Colorado typically add 2 to 5 days for transit, bringing the total to 7 to 14 business days from consult to doorstep.

Pricing falls outside insurance for most patients. Colorado Medicaid does not cover NMN or NR for longevity indications. Private insurers rarely cover compounded NAD+ precursors either. Expect to pay $80 to $200 per month out of pocket depending on dose, formulation (capsule vs. sublingual), and pharmacy markup.

NMN vs. NR: Which One Colorado Providers Prescribe

The two compounds share a destination (NAD+ biosynthesis) but take slightly different metabolic routes. NMN is a direct precursor to NAD+ via the enzyme NMNAT. NR enters through the NR kinase (NRK) pathway, first converting to NMN, then to NAD+ [9]. Both raise NAD+ levels in human studies. The clinical question is whether one outperforms the other.

A 2023 meta-analysis in the Journal of Nutritional Biochemistry pooled data from 15 randomized controlled trials of NMN and NR in humans and found that both compounds increased blood NAD+ by 40% to 90% at doses between 250 mg and 1 to 000 mg daily [10]. No head-to-head trial has definitively shown superiority of one molecule over the other for any clinical endpoint.

Colorado prescribers tend to favor NMN for patients seeking prescription-grade compounding because NR remains available as a supplement (Tru Niagen, 300 mg capsules). Some clinicians prescribe both: NMN via compounding and NR as an over-the-counter adjunct. Dose stacking should only happen under provider supervision to avoid excessive methyl donor depletion.

Sublingual NMN formulations are gaining traction. Bypass of first-pass hepatic metabolism may improve bioavailability, though peer-reviewed pharmacokinetic data comparing oral vs. sublingual NMN in humans remains limited. Providers who favor sublingual dosing cite unpublished pharmacokinetic curves showing faster time-to-peak NAD+ levels, but this claim awaits validation in a controlled trial.

Colorado-Specific Regulatory Considerations

Colorado's telehealth framework is among the most permissive in the western U.S. The state does not require an initial in-person visit before prescribing, and the Colorado Division of Insurance mandates telehealth parity for covered services under C.R.S. § 10-16-123 [3]. While compounded NMN itself is not an insurance-covered service, the telehealth consultation fee may be reimbursable if billed as a general evaluation and management (E/M) visit.

Prescriptions written by out-of-state providers for Colorado patients are valid as long as the prescriber holds an active Colorado medical license or practices under a state with an interstate compact recognized by Colorado (such as the Interstate Medical Licensure Compact). Colorado joined the IMLC in 2016, expanding access to prescribers licensed in any of the 40+ member states [11].

Transferring an existing NMN/NR prescription into Colorado is permitted. The receiving pharmacy contacts the originating pharmacy to verify the prescription, prescriber credentials, and remaining refills. No prior authorization is needed for compounded NMN because it sits outside the insurance formulary system. The process mirrors any standard controlled or non-controlled prescription transfer under Colorado pharmacy statutes.

Dosing, Timing, and Monitoring Protocols

Standard NMN dosing in Colorado longevity clinics starts at 250 mg once daily, taken in the morning. Circadian biology data from mouse models suggests NAD+ synthesis peaks during waking hours, and most providers extrapolate this timing preference to human patients [12]. After 4 to 8 weeks at 250 mg, providers may titrate to 500 mg or, less commonly, 1 to 000 mg daily based on clinical response and lab values.

NR dosing typically begins at 300 mg once daily (matching the Tru Niagen capsule strength) and may increase to 600 mg or 1 to 000 mg. The Martens et al. trial used 1 to 000 mg/day without significant adverse events in 24 participants over 6 weeks [7].

Side effects are generally mild. Flushing, mild GI discomfort, and transient headache have been reported across multiple trials at rates barely exceeding placebo. A 12-week RCT by Igarashi et al. (2022, N=31) found no clinically significant adverse events at NMN doses up to 1 to 250 mg/day [13].

Monitoring after initiation includes repeat labs at 8 to 12 weeks (NAD+ levels, CMP, fasting insulin, homocysteine), a symptom check-in via telehealth, and annual reassessment. Providers typically continue prescribing indefinitely if labs remain stable and the patient reports subjective benefit. No evidence supports a mandatory "cycling" protocol, though some clinicians implement periodic 4-week washouts based on theoretical concerns about feedback inhibition in the NAD+ salvage pathway.

Insurance, Cost, and Payment in Colorado

Colorado Medicaid does not reimburse NMN or NR for longevity or anti-aging purposes. Coverage exists only when a provider documents a specific ICD-10 indication that Medicaid recognizes (e.g., type 2 diabetes, E11.9), and even then, compounded formulations rarely qualify. Private insurers in Colorado (Anthem, Cigna, Kaiser Permanente of Colorado, UnitedHealthcare) follow similar patterns: NAD+ precursors are classified as experimental for non-diabetic indications.

The full out-of-pocket cost breaks down like this. Telehealth consultation: $99 to $250 for the initial visit, $49 to $150 for follow-ups. Compounded NMN (250 to 500 mg/day, 30-day supply): $80 to $200. Labs: $150 to $400 if ordered through the telehealth platform; less if run through a primary care provider and billed to insurance as routine metabolic screening.

HSA and FSA funds can typically be applied to the consultation fee and lab costs. The compounded medication itself qualifies for HSA/FSA spending only if the prescriber provides a letter of medical necessity, which most telehealth platforms generate automatically.